A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B

Hepatology International

Volumn 5, Issue 2, 2011, Pages 664-670

  Shin, Su Rin ^a   Yoo, Byung Chul ^b   Choi, Moon Seok ^b   Lee, Dong Ho ^c   Song, Soon Mi ^c   Lee, Joon Hyoek ^b   Koh, Kwang Cheol ^b   Paik, Seung Woon ^b  

^a Hallym University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

Clevudine; Entecavir; Hepatitis B virus

Indexed keywords

CLEVUDINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; ISOLEUCINE; METHIONINE; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYOPATHY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; VIRUS LOAD; VIRUS MUTATION;

EID: 79956272051     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-010-9238-7     Document Type: Article

References (29)

1. D Lavanchy 2004 Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 97 107 14996343 10.1046/j.1365-2893.2003.00487.x 1:STN:280: DC%2BD2c7gs1Whug%3D%3D (Pubitemid 38365759)
2. European Association for the Study of the Liver 2009 EASL clinical practice guidelines: management of chronic hepatitis B J Hepatol 50 227 242 10.1016/j.jhep.2008.10.001
3. C Niu E Murakami PA Furman 2008 Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes Antivir Ther 13 263 269 18505177 1:CAS:528:DC%2BD1cXlslWmtbc%3D (Pubitemid 351535377)
4. T Asselah O Lada R Moucari P Marcellin 2008 Clevudine: a promising therapy for the treatment of chronic hepatitis B Expert Opin Investig Drugs 17 1963 1974 19012511 10.1517/13543780802535760 1:CAS:528:DC%2BD1cXhtlyjtrvP
5. S Balakrishna Pai SH Liu YL Zhu CK Chu YC Cheng 1996 Inhibition of hepatitis B virus by a novel l-nucleoside, 2′-fluoro-5-methyl-beta-l- arabinofuranosyl uracil Antimicrob Agents Chemother 40 380 386 8834884 1:STN:280:DyaK28vjtFyjsA%3D%3D
6. BC Yoo JH Kim YH Chung KS Lee SW Paik SH Ryu, et al. 2007 Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B Hepatology 45 1172 1178 17464992 10.1002/hep.21629 1:CAS:528:DC%2BD2sXlslOju7w%3D (Pubitemid 46775779)
7. BC Yoo JH Kim TH Kim KC Koh SH Um YS Kim, et al. 2007 Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression Hepatology 46 1041 1048 17647293 10.1002/hep.21800 1:CAS:528:DC%2BD2sXht1aksr3J (Pubitemid 350144769)
8. J Summers WS Mason 2004 Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy Proc Natl Acad Sci USA 101 638 640 14699050 10.1073/pnas.0307422100 1:CAS:528:DC%2BD2cXmsFGmuw%3D%3D (Pubitemid 38084689)
9. Y Zhu T Yamamoto J Cullen J Saputelli CE Aldrich DS Miller, et al. 2001 Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis J Virol 75 311 322 11119601 10.1128/JVI.75.1.311-322.2001 1:CAS:528:DC%2BD3cXovV2jtbw%3D
10. IH Kim S Lee SH Kim SW Kim SO Lee ST Lee, et al. 2010 Treatment outcomes of clevudine versus lamivudine at week 48 in naïve patients with HBeAg positive chronic hepatitis B J Korean Med Sci 25 738 745 20436711 10.3346/jkms.2010.25.5.738 1:CAS:528:DC%2BC3cXnsVyjurw%3D
11. MH Kim KA Kim JS Lee HW Lee HJ Kim SG Yun, et al. 2009 Efficacy of 48-week clevudine therapy for chronic hepatitis B Korean J Hepatol 15 331 337 19783882 10.3350/kjhep.2009.15.3.331
12. SY Ko SY Kwon WH Choe BK Kim KH Kim CH Lee 2009 Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study Antivir Ther 14 585 590 19578244 1:CAS:528:DC%2BD1MXpvF2nu7Y%3D
13. HJ Kim DI Park JH Park YK Cho CI Sohn WK Jeon, et al. 2010 Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B Liver Int 30 834 840 20408946 10.1111/j.1478-3231.2010. 02245.x 1:CAS:528:DC%2BC3cXovFSjtbo%3D
14. J Dienstag 2008 Hepatitis B virus infection N Engl J Med 359 1486 1500 18832247 10.1056/NEJMra0801644 1:CAS:528:DC%2BD1cXhtFOru7bL
15. HJ Lee JR Eun CH Lee JS Hwang JI Suh BS Kim, et al. 2009 Long-term clevudine therapy in nucleos(t)ide-naive and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases Korean J Hepatol 15 179 192 19581770 10.3350/kjhep.2009.15.2.179
16. JS Lee ET Park SS Kang ES Gu JS Kim DS Jang, et al. 2010 Clevudine demonstrates potent antiviral activity in naive chronic hepatitis B patients Intervirology 53 83 86 19955812 10.1159/000264197 1:CAS:528:DC%2BC3cXhsl2iu7Y%3D
17. SY Kwon YK Park SH Ahn ES Cho WH Choe CH Lee, et al. 2010 Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients J Virol 84 4494 4503 20164224 10.1128/JVI.02066-09 1:CAS:528:DC%2BC3cXlt1Kiu7o%3D
18. SK Fung HB Chae RJ Fontana H Conjeevaram J Marrero K Oberhelman, et al. 2006 Virologic response and resistance to adefovir in patients with chronic hepatitis B J Hepatol 44 283 290 16338024 10.1016/j.jhep.2005.10.018 1:CAS:528:DC%2BD28Xktl2qsA%3D%3D (Pubitemid 43069209)
19. MF Yuen E Sablon CK Hui HJ Yuan H Decraemer CL Lai 2001 Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy Hepatology 34 785 791 11584376 10.1053/jhep.2001. 27563 1:CAS:528:DC%2BD3MXns1Kisrc%3D (Pubitemid 32928004)
20. F Zoulim T Poynard F Degos A Slama A El Hasnaoui P Blin, et al. 2006 A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine J Viral Hepat 13 278 288 16611195 10.1111/j.1365-2893.2005.00712.x 1:STN:280:DC%2BD283gsFOqtA%3D%3D
21. BK Kim J Oh SY Kwon, et al. 2009 Clevudine myopathy in patients with chronic hepatitis B J Hepatol 51 829 834 19615776 10.1016/j.jhep.2009.04.019
22. JI Seok DK Lee CH Lee MS Park SY Kim HS Kim, et al. 2009 Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA Hepatology 49 2080 2086 19333909 10.1002/hep.22959 1:CAS:528:DC%2BD1MXotVCmurg%3D
23. WY Tak SY Park MK Jung SW Jeon CM Cho YO Kweon, et al. 2009 Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients Hepatol Res 39 944 947 19712273 10.1111/j.1872-034X.2009.00515.x 1:CAS:528: DC%2BD1MXht12hu7jO
24. WY Tak SY Park CM Cho MK Jung SW Jeon YO Kweon, et al. 2010 Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy J Hepatol 53 261 266 20466447 10.1016/j.jhep.2010.03.006 1:CAS:528: DC%2BC3cXosVGrsb4%3D
25. Kim JH, Yim HJ, Jung ES, Jung YK, Kim JH, Seo YS, et al. Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48. J Viral Hepat 2010. doi: 10.1111/j.1365-2893.2010.01304.x
26. Jang JH, Kim JW, Jeong SH, Myung HJ, Kim HS, Park YS, et al. Clevudine for chronic hepatitis B: Antiviral response, predictors of response, and development of myopathy. J Viral Hepat 2010. doi: 10.1111/j.1365-2893.2010. 01281.x
27. RD Fleischer AS Lok 2009 Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B J Hepatol 51 787 791 19665816 10.1016/j.jhep.2009.06.011 1:CAS:528:DC%2BD1MXhtFagt7%2FJ
28. YF Liaw E Gane N Leung S Zeuzem Y Wang CL Lai, et al. 2009 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 486 495 19027013 10.1053/j.gastro.2008.10.026 1:CAS:528:DC%2BD1MXislOhtLs%3D
29. JE Yeon 2008 Technique for the early detection of drug-resistant HBV DNA during antiviral therapy Intervirology 51 1 7 10 18544942 10.1159/000122593 1:CAS:528:DC%2BD1cXmvFGns7g%3D (Pubitemid 351821836)